Moors & Cabot, Inc. Biomarin Pharmaceutical Inc Transaction History

Moors & Cabot, Inc.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$74.43 - $92.22 $1,488 - $1,844	-20 Reduced 0.58%	3,450 $284,000
Q1 2024 May 08, 2024	BUY	$83.81 - $99.0 $40,396 - $47,718	482 Added 16.13%	3,470 $303,000
Q4 2023 Feb 14, 2024	BUY	$76.22 - $98.51 $1,676 - $2,167	22 Added 0.74%	2,988 $288,000
Q3 2023 Nov 07, 2023	SELL	$85.07 - $94.48 $110,420 - $122,635	-1,298 Reduced 30.44%	2,966 $262,000
Q2 2023 Aug 09, 2023	SELL	$86.68 - $100.3 $17,249 - $19,959	-199 Reduced 4.46%	4,264 $369,000
Q1 2023 May 04, 2023	BUY	$87.74 - $117.27 $2,895 - $3,869	33 Added 0.74%	4,463 $433,000
Q4 2022 Feb 09, 2023	SELL	$80.93 - $108.63 $113,706 - $152,625	-1,405 Reduced 24.08%	4,430 $458,000
Q4 2022 Feb 06, 2023	BUY	$80.93 - $108.63 $110,712 - $148,605	1,368 Added 30.62%	5,835 $603,000
Q3 2022 Nov 07, 2022	SELL	$82.16 - $96.94 $107,218 - $126,506	-1,305 Reduced 22.61%	4,467 $379,000
Q1 2022 May 13, 2022	SELL	$74.28 - $92.69 $4,679 - $5,839	-63 Reduced 1.08%	5,772 $445,000
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $86,064 - $109,764	1,200 Added 25.89%	5,835 $516,000
Q3 2021 Dec 08, 2021	BUY	$74.77 - $85.47 $346,558 - $396,153	4,635 New	4,635 $357,000
Q3 2021 Nov 05, 2021	SELL	$74.77 - $85.47 $331,231 - $378,632	-4,430 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$75.51 - $84.79 $334,509 - $375,619	4,430 New	4,430 $370,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Moors & Cabot, Inc., based on Form 13F filings with the SEC.

Stay updated on Moors & Cabot, Inc. with notifications on news.